Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs.

The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk. Choosing between these two stocks may come down to ...

Shares of Pfizer and Moderna fell on Friday after a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children. The report comes as Health and Human ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has ...